There are 2137 resources available
734P - Kidney manifestations in patients with hereditary leiomyomatosis and renal cell cancer syndrome (LHRCC) in Spain
Presenter: Ana Beatriz Sanchez
Session: E-Poster Display
Resources:
Abstract
735P - Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study
Presenter: Zoé Guillaume
Session: E-Poster Display
Resources:
Abstract
736P - Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial
Presenter: Giuseppe Procopio
Session: E-Poster Display
Resources:
Abstract
737P - Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place
Presenter: Aafke Meerveld-Eggink
Session: E-Poster Display
Resources:
Abstract
738P - Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal carcinoma
Presenter: Lorena Incorvaia
Session: E-Poster Display
Resources:
Abstract
739P - Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b)
Presenter: Marco Stellato
Session: E-Poster Display
Resources:
Abstract
740P - Response assessment in advanced renal cell carcinoma (mRCC) patients (pts) treated by Nivolumab (N) + Ipilimumab (I): CT volumetric measurement versus RECIST 1.1 response criteria
Presenter: Quentin Minault
Session: E-Poster Display
Resources:
Abstract
741P - Clinical outcomes stratified by Charlson Comorbidity Index (CCI) score from a retrospective study of patients with advanced renal cell carcinoma (aRCC) who received cabozantinib as part of the UK Managed Access Program (MAP)
Presenter: Kate Fife
Session: E-Poster Display
Resources:
Abstract
742P - Activation of the WNT signaling pathway correlates with innate resistance to immune checkpoint therapies in clear cell renal cell carcinoma
Presenter: Xinan Sheng
Session: E-Poster Display
Resources:
Abstract
743P - Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Luigi Cerbone
Session: E-Poster Display
Resources:
Abstract